6-MAPB

Last updated
6-MAPB
6-MAPB.svg
Clinical data
Other names1-(Benzofuran-6-yl)-N-methylpropan-2-amine
Routes of
administration 		Oral
Drug class Monoamine releasing agent; Serotonin 5-HT1B receptor agonist
Legal status
Legal status
Identifiers
  • 1-(Benzofuran-6-yl)-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C12H15NO
Molar mass 189.258 g·mol−1
3D model (JSmol)
  • CC(NC)CC1=CC(OC=C2)=C2C=C1
  • InChI=1S/C12H15NO/c1-9(13-2)7-10-3-4-11-5-6-14-12(11)8-10/h3-6,8-9,13H,7H2,1-2H3
  • Key:QLAAURQYEAEHBO-UHFFFAOYSA-N

6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA. [1] [2] [3] [4] It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT1B receptor agonist. [5] The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives.[ citation needed ] 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014. [6] [7] It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects. [8]

Contents

Interactions

See also

References

  1. ↑ Welter J, Brandt SD, Kavanagh P, Meyer MR, Maurer HH (May 2015). "Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques" (PDF). Analytical and Bioanalytical Chemistry. 407 (12): 3457–3470. doi:10.1007/s00216-015-8552-2. PMID   25711990. S2CID   5475974.
  2. ↑ Welter-Luedeke J, Maurer HH (February 2016). "New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems". Therapeutic Drug Monitoring. 38 (1): 4–11. doi:10.1097/FTD.0000000000000240. PMID   26327309. S2CID   20737913.
  3. ↑ Shimshoni JA, Winkler I, Golan E, Nutt D (January 2017). "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn-Schmiedeberg's Archives of Pharmacology. 390 (1): 15–24. doi:10.1007/s00210-016-1297-4. hdl: 10044/1/43622 . PMID   27650729. S2CID   253741131.
  4. ↑ Brandt SD, Walters HM, Partilla JS, Blough BE, Kavanagh PV, Baumann MH (December 2020). "The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats". Psychopharmacology. 237 (12): 3703–3714. doi:10.1007/s00213-020-05648-z. PMC   7686291 . PMID   32875347.
  5. ↑ US 20230150963, Matthew Baggott,"Advantageous benzofuran compositions for mental disorders or enhancement",published 2023 May 18, assigned to Tactogen
  6. ↑ King LA (2014). "New phenethylamines in Europe". Drug Test Anal. 6 (7–8): 808–818. doi:10.1002/dta.1570. PMID   24574327.
  7. ↑ https://isomerdesign.com/bitnest/external/EMCDDA/New-Drugs-In-Europe-2013
  8. ↑ "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. Retrieved 2013-07-10.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.